Personalized treatment of pain

Current Rheumatology Reports

Volumn 15, Issue 1, 2013, Pages

  Ablin, Jacob N ^a   Buskila, Dan ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Central sensitization; Chronic pain; Conditioned pain modulation (CPM); Fibromyalgia; Genetics; Narrative medicine; Personalized medicine; Pharmacogenetics

Indexed keywords

AMITRIPTYLINE; ANTICOAGULANT AGENT; CANNABIS; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DULOXETINE; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHADONE; MILNACIPRAN; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CHRONIC PAIN; COGNITIVE THERAPY; COMORBIDITY; CONDITIONED PAIN MODULATION; CONFUSION; CONSTIPATION; DROWSINESS; DRUG CLEARANCE; DRUG METABOLISM; EXERCISE; GENETIC TRAIT; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; MYALGIA; NARRATIVE THERAPY; NAUSEA; NOCICEPTION; PAIN; PAIN ASSESSMENT; PATIENT CARE PLANNING; PERSONALIZED MEDICINE; PHARMACOGENETICS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84870459991     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0298-7     Document Type: Article

References (47)

1. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum. 2007;36(6):339-56. (Pubitemid 46776822)
2. Sessle BJ. Peripheral and central mechanisms of orofacial inflammatory pain. Int Rev Neurobiol. 2011;97:179-206.
3. Verne GN, Price DD. Irritable bowel syndrome as a common precipitant of central sensitization. Curr Rheumatol Rep. 2002;4(4):322-8.
4. & Staud R. Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. Curr Rheumatol Rep. 2011;13 (6):513-20. A recent review clarifying the overlap between seemingly disconnected aspects of chronic pain.
5. Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther. 2011;13(2):211.
6. Clauw DJ, Witter J. Pain and rheumatology: thinking outside the joint. Arthritis Rheum. 2009;60(2):321-4.
7. & Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing. 2012. [Epub ahead of print]. Well conducted recent study demonstrating the efficacy of an SNRI in a traditional "nociceptive" pain condition.
8. Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW. Duloxetine use in chronic low back pain: treatment patterns and costs. PharmacoEconomics. 2012;30(7):595-609.
9. Wolfe F. Fibromyalgianess. Arthritis Rheum. 2009;61(6):715-6.
10. Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011;33(4):433-8.
11. Eisinger J. Dysautonomia, fibromyalgia and reflex dystrophy. Arthritis Res Ther. 2007;9(4):105.
12. Sarzi-Puttini P, Atzeni F, Diana A, Doria A, Furlan R. Increased neural sympathetic activation in fibromyalgia syndrome. Ann N Y Acad Sci. 2006;1069:109-17. (Pubitemid 43989854)
13. Ursini F, Naty S, Grembiale RD. Fibromyalgia and obesity: the hidden link. Rheumatol Int. 2011;31(11):1403-8.
14. Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48(10):2916-22. (Pubitemid 37280621)
15. Edwards RR, Bingham III CO, Bathon J, Haythornthwaite JA. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Rheum. 2006;55(2):325-32.
16. Thorn BE, Pence LB, Ward LC, Kilgo G, Clements KL, Cross TH, et al. A randomized clinical trial of targeted cognitive behavioral treatment to reduce catastrophizing in chronic headache sufferers. J Pain. 2007;8(12):938-49. (Pubitemid 350161437)
17. Simon GE, Savarino J, Operskalski B,Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163(1):41-7.
18. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32(4):304-15. (Pubitemid 44502005)
19. Riley J, Ross JR, Rutter D, Wells AU, Goller K, Du BR, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2006;14(1):56-64. (Pubitemid 43119598)
20. & Branford R, Droney J, Ross J. Opioid genetics: the key to personalized pain control? Clin Genet. 2012;1399-1404. A comprehensive up-to-date review of the topic of opioid pharmacogenetics and pharmacokinetics.
21. Leandro-Garcia LJ, Leskela S, Montero-Conde C, Landa I, Lopez- Jimenez E, Leton R, et al. Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis. Anal Biochem. 2009;389(1):74-6.
22. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol Sci. 2011;120(1):1-13.
23. Stamer UM, Zhang L, Stuber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics. 2010;11 (6):843-64.
24. Stamer UM, Stuber F. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype. Anaesthesia. 2007;62(12):1294-5. (Pubitemid 350060534)
25. Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003;105(1-2):231-8. (Pubitemid 37162492)
26. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY, et al. Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1 G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery. Eur J Anaesthesiol. 2011;28(4):245-50.
27. Xu Y, Zhang Y, Zhou F, Zheng Y, Zhu X. Human pregnane X receptor-mediated transcriptional regulation of CYP3A4 by extracts of 7 traditional Chinese medicines. Zhongguo Zhong Yao Za Zhi. 2011;36(11):1524-7.
28. Tournier N, Decleves X, Saubamea B, Scherrmann JM, Cisternino S. Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications for neuropsychopharmacology. Curr Pharm Des. 2011;17(26):2829-42.
29. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008;83(4):559-66. (Pubitemid 351417058)
30. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48(10):1232-9. (Pubitemid 39490855)
31. Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5 (5):324-36. (Pubitemid 41486231)
32. Ali ZK, Kim RJ, Ysla FM. CYP2C9 polymorphisms: considerations in NSAID therapy. Curr Opin Drug Discov Devel. 2009;12 (1):108-14.
33. Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005;97(5):296-301. (Pubitemid 41608122)
34. Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004;59(1):5-12. (Pubitemid 38765554)
35. LLerena A, Dorado P, Berecz R, Gonzalez AP, Penas-LLedo EM. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol. 2004;59(12):869-73. (Pubitemid 38337438)
36. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161(9):1575-80. (Pubitemid 39201453)
37. McAlpine DE, Biernacka JM, Mrazek DA, O'Kane DJ, Stevens SR, Langman LJ, et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit. 2011;33(1):14-20.
38. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299(5610):1240-3. (Pubitemid 36237467)
39. Martinez-Jauand M, Sitges C, Rodriguez V, Picornell A, Ramon M, Buskila D et al. Pain sensitivity in fibromyalgia is associated with catechol-O- methyltransferase (COMT) gene. Eur J Pain 2012
40. & Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain. 2012;153(6):1193-8. A novel study demonstrating the efficacy of CPM measurement in predicting the response to SNRI treatment.
41. Pud D, Granovsky Y, Yarnitsky D. The methodology of experimentally induced diffuse noxious inhibitory control (DNIC)-like effect in humans. Pain. 2009;144(1-2):16-9.
42. Lev R, Granovsky Y, Yarnitsky D. Orbitofrontal disinhibition of pain in migraine with aura: an interictal EEG-mapping study. Cephalalgia. 2010;30(8):910-8.
43. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain. 2005;114(1-2):295-302. (Pubitemid 40279112)
44. Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain. 2000;88(1):69-78.
45. Murray M. Narrative psychology. In: Smith JA, editor. Qualitative psychology: A practical guide to research methods. London: Sage; 2008. p. 111-32.
46. Elliott J. Using narrative in social research: Qualitative and quantitative approaches. London: Sage; 2005.
47. & McMahon L, Murray C, Simpson J. The potential benefits of applying a narrative analytic approach for understanding the experience of fibromyalgia: a review. Disabil Rehabil. 2012;34(13):1121-30. Recent and up-to-date coverage of the narrative approach.